<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36308529</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Motor, cognitive and behavioural profiles of C9orf72 expansion-related amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>898</StartPage><EndPage>908</EndPage><MedlinePgn>898-908</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11433-z</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Amyotrophic lateral sclerosis (ALS) individuals carrying the hexanucleotide repeat expansion (HRE) in the C9orf72 gene (C9Pos) have been described as presenting distinct features compared to the general ALS population (C9Neg). We aim to identify the phenotypic traits more closely associated with the HRE and analyse the role of the repeat length as a modifier factor.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied a cohort of 960 ALS patients (101 familial and 859 sporadic cases). Motor phenotype was determined using the MRC scale, the lower motor neuron score (LMNS) and the Penn upper motor neuron score (PUMNS). Neuropsychological profile was studied using the Italian version of the Edinburgh Cognitive and Behavioral ALS Screen (ECAS), the Frontal Behavioral Inventory (FBI), the Beck Depression Inventory-II (BDI-II) and the State-Trait Anxiety Inventory (STAI). A two-step PCR protocol and Southern blotting were performed to determine the presence and the size of C9orf72 HRE, respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">C9orf72 HRE was detected in 55/960 ALS patients. C9Pos patients showed a younger onset, higher odds of bulbar onset, increased burden of UMN signs, reduced survival and higher frequency of concurrent dementia. We found an inverse correlation between the HRE length and the performance at ECAS ALS-specific tasks (P&#x2009;=&#x2009;0.031). Patients also showed higher burden of behavioural disinhibition (P&#x2009;=&#x2009;1.6&#x2009;&#xd7;&#x2009;10<sup>-4</sup>), lower degrees of depression (P&#x2009;=&#x2009;0.015) and anxiety (P&#x2009;=&#x2009;0.008) compared to C9Neg cases.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study provides an extensive characterization of motor, cognitive and behavioural features of C9orf72-related ALS, indicating that the C9orf72 HRE size may represent a modifier of the cognitive phenotype.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Eleonora</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poletti</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maranzano</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Dino Ferrari Center", Department of Pathophysiology and Transplantation, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peverelli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solca</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombrita</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torre</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tiloca</LastName><ForeName>Cinzia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verde</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Dino Ferrari Center", Department of Pathophysiology and Transplantation, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonetti</LastName><ForeName>Ruggero</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Dino Ferrari Center", Department of Pathophysiology and Transplantation, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morelli</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratti</LastName><ForeName>Antonia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biotechnology and Translational Medicine, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Dino Ferrari Center", Department of Pathophysiology and Transplantation, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5963-7426</Identifier><AffiliationInfo><Affiliation>Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Universit&#xe0; degli Studi di Milano, P.le Brescia 20, 20149, Milan, Italy. n.ticozzi@auxologico.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Dino Ferrari Center", Department of Pathophysiology and Transplantation, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy. n.ticozzi@auxologico.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurol. 2023 Jun;270(6):3284-3285</RefSource><PMID Version="1">36913039</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042622" MajorTopicYN="N">DNA Repeat Expansion</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Genetics</Keyword><Keyword MajorTopicYN="N">Motor neuron disease</Keyword></KeywordList><CoiStatement>E.Colombo, B. Poletti, A. Maranzano, S. Peverelli, F. Solca, C. Colombrita, S. Torre, C. Tiloca, F. Verde, R. Bonetti, L. Carelli, C. Morelli report no disclosures. A. Ratti received research funding from AriSLA. V. Silani received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, Liquidweb Srl, and Novartis Pharma AG. He receives or has received research support from the Italian Ministry of Health, AriSLA, and E-Rare Joint Transnational Call. He is on the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, European Neurology, American Journal of Neurodegenerative Diseases, and Frontiers in Neurology. N. Ticozzi received compensation for consulting services from Amylyx Pharmaceuticals and Zambon Biotech SA. He received research funding from the Italian Ministry of Health and AriSLA. He is Associate Editor for Frontiers in Aging Neuroscience.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>11</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36308529</ArticleId><ArticleId IdType="pmc">PMC9886586</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11433-z</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11433-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mejzini R, Fletcher LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA. ALS genetics, mechanisms, and therapeutics: where are we now? Front Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Umoh ME, Fournier C, Li Y, Polak M, Shaw L, Landers JE, Hu W, Gearing M, Glass JD. Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology. 2016;87:1024&#x2013;1030. doi: 10.1212/WNL.0000000000003067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003067</ArticleId><ArticleId IdType="pmc">PMC5027809</ArticleId><ArticleId IdType="pubmed">27488601</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyers J, Banchi EG, Latouche M. C9ORF72: what it is, what it does, and why it matters. Front Cell Neurosci. 2021;15:661447. doi: 10.3389/fncel.2021.661447.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2021.661447</ArticleId><ArticleId IdType="pmc">PMC8131521</ArticleId><ArticleId IdType="pubmed">34025358</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Corrado L, Castellotti B, Del Bo R, Fogh I, Cereda C, Tiloca C, D&#x2019;Ascenzo C, Bagarotti A, Pesnati V, Ranieri M, Gagliardi S, Calini D, Mazzini L, Taroni F, Corti S, Ceroni M, Oggioni GD, Lin K, Powell JF, Sorar&#xf9; G, Ticozzi N, Comi GP, D&#x2019;Alfonso S, Gellera C, Silani V, SLAGEN Consortium C9ORF72 repeat expansion in a large Italian ALS cohort: evidence of a founder effect. Neurobiol Aging. 2012;33:2528.e7&#x2013;e14. doi: 10.1016/j.neurobiolaging.2012.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.06.008</ArticleId><ArticleId IdType="pubmed">22766072</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A, Borghero G, Restagno G, Mora G, Drepper C, Trajnor BJ, Sendtner M, Brunetti M, Ossola I, Calvo A, Pugliatti M, Sotgiu MA, Murru MR, Marrosu MG, Marrosu F, Marinou K, Mandrioli J, Sola P, Caponnetto C, Mancardi G, Mandich P, La Bella V, Spataro R, Conte A, Monsurr&#xf2; MR, Tedeschi G, Pisano F, Bartolomei I, Salvi F, Lauria Pinter G, Simone I, Logroscino G, Gambardella A, Quattrone A, Lunetta C, Volanti P, Zollino M, Penco S, Battistini S, ITALSGEN consortium. Renton AE, Majounie A, Abramzon Y, Conforti FL, Giannini F, Corbo M, Sabatelli M. Clinical characteristics of patients with familial amyotrophic lateral sclerosis carrying the pathogenic GGGGCC hexanucleotide repeat expansion of C9ORF72. Brain. 2012;135:784&#x2013;793. doi: 10.1093/brain/awr366.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr366</ArticleId><ArticleId IdType="pmc">PMC3286333</ArticleId><ArticleId IdType="pubmed">22366794</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart H, Rutherford NJ, Briemberg H, Briemberg H, Krieger C, Cashman N, Fabros M, Baker M, Fok A, DeJesus-Hernandez M, Eisen A, Rademakers R, Mackenzie IRA. Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathol. 2012;123:409&#x2013;417. doi: 10.1007/s00401-011-0937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0937-5</ArticleId><ArticleId IdType="pmc">PMC3322555</ArticleId><ArticleId IdType="pubmed">22228244</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin DJ, McMillan CT, Brettschneider J, Libon DJ, Powers J, Rascovsky K, Toledo JB, Boller A, Bekisz J, Chandrasekaran K, McCarty Wood E, Shaw LM, Woo JH, Cook PA, Wolk DA, Arnold SE, Van Deerlin VM, McCluskey LF, Elman L, Lee VM-Y, Trojanowski JQ, Grossman M. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:163&#x2013;169. doi: 10.1136/jnnp-2012-303507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303507</ArticleId><ArticleId IdType="pmc">PMC3543474</ArticleId><ArticleId IdType="pubmed">23117491</ArticleId></ArticleIdList></Reference><Reference><Citation>Trojsi F, Siciliano M, Femiano C, Santangelo G, Lunetta C, Calvo A, Moglia C, Marinou K, Ticozzi N, Ferro C, Scial&#xf2; C, Sorar&#xf9; G, Conte A, Falzone YM, Tortelli R, Russo M, Sansone VA, Chi&#xf2; A, Mora G, Silani V, Volanti P, Caponnetto C, Querin G, Sabatelli M, Riva N, Logroscino G, Messina S, Fasano A, Monsurr&#xf2; MR, Tedeschi G, Mandrioli J. Comparative analysis of C9orf72 and sporadic disease in a large multicenter ALS population: the effect of male sex on survival of C9orf72 positive patients. Front Neurosci. 2019;13:485. doi: 10.3389/fnins.2019.00485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.00485</ArticleId><ArticleId IdType="pmc">PMC6534038</ArticleId><ArticleId IdType="pubmed">31156370</ArticleId></ArticleIdList></Reference><Reference><Citation>Snowden JS, Harris J, Richardson A, Rollinson S, Thompson JC, Neary D, Mann DMA, Pickering-Brown S. Frontotemporal dementia with amyotrophic lateral sclerosis: a clinical comparison of patients with and without repeat expansions in C9orf72. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:172&#x2013;176. doi: 10.3109/21678421.2013.765485.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.765485</ArticleId><ArticleId IdType="pubmed">23421625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Peverelli S, D&#x2019;Adda E, Colombrita C, Gennuso M, Prelle A, Silani V. Genetic and epigenetic disease modifiers in an Italian C9orf72 family expressing ALS, FTD or PD clinical phenotypes. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23:292&#x2013;298. doi: 10.1080/21678421.2021.1962355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2021.1962355</ArticleId><ArticleId IdType="pubmed">34382491</ArticleId></ArticleIdList></Reference><Reference><Citation>Gijselinck I, Van Mossevelde S, van der Zee J, Sieben A, Engelborghs S, De Bleecker J, Ivanoiu A, Deryck O, Edbauer D, Zhang M, Heeman B, B&#xe4;umer V, Van den Broeck M, Mattheijssens M, Peeters K, Rogaeva E, De Jonghe P, Cras P, Martin J-J, de Deyn PP, Cruts M, Van Broeckhoven C. The C9orf72 repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. Mol Psychiatry. 2016;21:1112&#x2013;1124. doi: 10.1038/mp.2015.159.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.159</ArticleId><ArticleId IdType="pmc">PMC4960451</ArticleId><ArticleId IdType="pubmed">26481318</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck J. C9orf72 and the Care of the Patient With ALS or FTD. Progress and Recommendations After 10 Years. Neurol Genet. 2021;7:e542. doi: 10.1212/NXG.0000000000000542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXG.0000000000000542</ArticleId><ArticleId IdType="pmc">PMC7862089</ArticleId><ArticleId IdType="pubmed">33575483</ArticleId></ArticleIdList></Reference><Reference><Citation>Amado DA, Davidson BL. Gene therapy for ALS: a review. Mol Ther. 2021;29:3345&#x2013;3358. doi: 10.1016/j.ymthe.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8636154</ArticleId><ArticleId IdType="pubmed">33839324</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng H-J, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, Martin S, McDermott CJ, Thompson AG, Pinto S, Kobeleva X, Rosenbohm A, Stubendorff B, Sommer H, Middelkoop BM, Dekker AM, van Vugt JJFA, van Rheenen W, Vajda A, Heverin M, Kazoka M, Hollinger H, Gromicho M, K&#xf6;rner S, Ringer TM, R&#xf6;diger A, Gunkel A, Shaw CE, Bredenoord AL, van Es MA, Corcia P, Couratier P, Weber M, Grosskreutz J, Ludolph AC, Petri S, de Carvalho M, Van Damme P, Talbot K, Turner MR, Shaw PJ, Al-Chalabi A, Chi&#xf2; A, Hardiman O, Moons KGM, Velfink JH, van den Berg LH. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;433. doi: 10.1016/S1474-4422(18)30089-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(18)30089-9</ArticleId><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotrophic Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Beltran S, Lautrette G, Bakkouche S, Couratier P. Staging amyotrophic lateral sclerosis: a new focus on progression. Rev Neurol. 2019;175:277&#x2013;282. doi: 10.1016/j.neurol.2018.09.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurol.2018.09.017</ArticleId><ArticleId IdType="pubmed">30606512</ArticleId></ArticleIdList></Reference><Reference><Citation>Devine MS, Ballard E, O&#x2019;Rourke P, Kiernan MC, Mccombe PA, Henderson RD. Targeted assessment of lower motor neuron burden is associated with survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Scler and Frontotemporal Degener. 2016;17:184&#x2013;190. doi: 10.3109/21678421.2015.1125502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1125502</ArticleId><ArticleId IdType="pubmed">26700804</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinn C, Edmundson C, Dahodwala N, Elman L. Reliable and efficient scale to assess upper motor neuron disease burden in amyotrophic lateral sclerosis. Muscle Nerve. 2020;61:508&#x2013;511. doi: 10.1002/mus.26764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26764</ArticleId><ArticleId IdType="pubmed">31743477</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Solca F, Carelli L, Madotto F, Lafronza A, Faini A, Monti A, Zago S, Calini D, Tiloca C, Doretti A, Verde F, Ratti A, Ticozzi N, Abrahams S, Silani V. The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS) Amyotroph Lateral Scler Frontotemporal Degener. 2016;17:489&#x2013;498. doi: 10.1080/21678421.2016.1183679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1183679</ArticleId><ArticleId IdType="pubmed">27219526</ArticleId></ArticleIdList></Reference><Reference><Citation>Gosselt IK, Nijboer TCW, Van Es MA. An overview of screening instruments for cognition and behavior in patients with ALS: selecting the appropriate tool for clinical practice. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:324&#x2013;336. doi: 10.1080/21678421.2020.1732424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2020.1732424</ArticleId><ArticleId IdType="pubmed">32157912</ArticleId></ArticleIdList></Reference><Reference><Citation>Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546&#x2013;1554. doi: 10.1212/wnl.51.6.1546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.51.6.1546</ArticleId><ArticleId IdType="pubmed">9855500</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, van Swieten JC, Seelaar H, Dopper EGP, Onyike CU, Hillis AE, Josephs KA, Boeve BF, Kertesz A, Seeley WW, Rankin KP, Johnson JK, Gorno-Tempini M-L, Rosen H, Prioleau-Latham CE, Lee A, Kipps CM, Lillo P, Piguet O, Rohrer JD, Rossor MN, Warren JD, Fox NC, Galasko D, Salmon DP, Black SE, Mesulam M, Weintraub S, Dickerson BC, Diehl-Schmid J, Pasquier F, Deramecourt V, Lebert F, Pijnenburg Y, Chow TW, Manes F, Grafman J, Cappa SF, Freedman M, Grossman M, Miller BL. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134:2456&#x2013;2477. doi: 10.1093/brain/awr179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awr179</ArticleId><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, Mioshi E, Roberts-South A, Benatar M, Hortob&#xe1;gyi T, Rosenfeld J, Silani V, Ince PG, Turner MR. Amyotrophic lateral sclerosis&#x2014;frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:153&#x2013;174. doi: 10.1080/21678421.2016.1267768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YP, Gorenstein C. Psychometric properties of the Beck Depression Inventory-II: a comprehensive review. Braz J Psychiatry. 2013;35:416&#x2013;431. doi: 10.1590/1516-4446-2012-1048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1516-4446-2012-1048</ArticleId><ArticleId IdType="pubmed">24402217</ArticleId></ArticleIdList></Reference><Reference><Citation>Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Palo Alto: Consulting Psychologists Press; 1983.</Citation></Reference><Reference><Citation>Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, Campbell T, Uphill J, Borg A, Fratta P, Orrell RW, Malaspina A, Rowe J, Brown J, Hodges J, Sidle K, Polke JM, Houlden H, Schott JM, Fox NC, Rossor MN, Tabrizi SJ, Isaacs AM, Hardy J, Warren JD, Collinge J, Mead S. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet. 2013;92:345&#x2013;353. doi: 10.1016/j.ajhg.2013.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajhg.2013.01.011</ArticleId><ArticleId IdType="pmc">PMC3591848</ArticleId><ArticleId IdType="pubmed">23434116</ArticleId></ArticleIdList></Reference><Reference><Citation>Theuns J, Verstraeten A, Sleegers K, Wauters E, Gijselinck I, Smolders S, Crostiers D, Corsmit E, Elinck E, Sharma M, Kr&#xfc;ger R, Lesage S, Brice A, Chung SJ, Kim M-J, Kim YJ, Ross OA, Wszolek ZK, Rogaeva E, Xi Z, Lang AE, Klein C, Weissbach A, Mellick GD, Silburn PA, Hadjigeorgiou GM, Dardiotis E, Hattori N, Ogaki K, Tan E-K, Zhao Y, Aasly J, Valente EM, Petrucci S, Annesi G, Quattrone A, Ferrarese C, Brighina L, Deutschl&#xe4;nder A, Puschmann A, Nilsson C, Garraux G, LeDoux MS, Pfeiffer RF, Boczarska-Jedynak M, Opala G, Maranganore DM, Engelborghs S, De Deyn PP, Cras P, Cruts M, Broeckhoven V, GEO-PD Consortium Global investigation and meta-analysis of the C9orf72 (G4C2)n repeat in Parkinson disease. Neurology. 2014;83:1906&#x2013;1913. doi: 10.1212/WNL.0000000000001012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000001012</ArticleId><ArticleId IdType="pmc">PMC4248456</ArticleId><ArticleId IdType="pubmed">25326098</ArticleId></ArticleIdList></Reference><Reference><Citation>Ticozzi N, Tiloca C, Calini D, Gagliardi S, Altieri A, Colombrita C, Cereda C, Ratti A, Pezzoli G, Borroni B, Goldwurm S, Padovani A, Silani V. C9orf72 repeat expansions are restricted to the ALS-FTD spectrum. Neurobiol Aging. 2014;35:936.e13&#x2013;e17. doi: 10.1016/j.neurobiolaging.2013.09.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.09.037</ArticleId><ArticleId IdType="pubmed">24169076</ArticleId></ArticleIdList></Reference><Reference><Citation>Iazzolino B, Peotta L, Zucchetti JP, Canosa A, Manera U, Vasta R, Grassano M, Palumbo F, Brunetti M, Barberis M, Sbaiz L, Moglia C, Calvo A, Chi&#xf2; A. Differential neuropsychological profile of patients with amyotrophic lateral sclerosis with and without C9orf72 mutation. Neurology. 2021;96:e141&#x2013;e152. doi: 10.1212/WNL.0000000000011093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000011093</ArticleId><ArticleId IdType="pubmed">33106391</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Mossevelde S, Van der Zee J, Cruts M, Van Broeckhoven C. Relationship between C9orf72 repeat size and clinical phenotype. Curr Opin Genet Dev. 2017;44:117&#x2013;124. doi: 10.1016/j.gde.2017.02.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gde.2017.02.008</ArticleId><ArticleId IdType="pubmed">28319737</ArticleId></ArticleIdList></Reference><Reference><Citation>Dols-Icardo O, Garc&#xed;a-Redondo A, Rojas-Garc&#xed;a R, S&#xe1;nchez-Valle R, Noguera A, G&#xf3;mez-Tortosa E, Pastor P, Hern&#xe1;ndez I, Esteban-P&#xe9;rez J, Su&#xe1;rez-Calvet M, Ant&#xf3;n-Aguirre S, Amer G, Ortega-Cubero S, Blesa R, Fortea J, Alcolea D, Capdevilla A, Antonell A, Llad&#xf3; M-B, Mora JS, Gal&#xe1;n-D&#xe1;vila RD, Rivera FJ, Lle&#xf3; A, Clarim&#xf3;n J. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum Mol Genet. 2014;23:749&#x2013;754. doi: 10.1093/hmg/ddt460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt460</ArticleId><ArticleId IdType="pubmed">24057670</ArticleId></ArticleIdList></Reference><Reference><Citation>Suh E, Lee EB, Neal D, Wood EM, Toledo JB, Rennert L, Irwin DJ, McMillan CT, Krock B, Elman LB, McCluskey LF, Grossman M, Xie SX, Trojanowski JQ, Van Deerlin VM. Semi-automated quantification of C9orf72 expansion size reveals inverse correlation between hexanucleotide repeat number and disease duration in frontotemporal degeneration. Acta Neuropathol. 2015;130:363&#x2013;372. doi: 10.1007/s00401-015-1445-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1445-9</ArticleId><ArticleId IdType="pmc">PMC4545720</ArticleId><ArticleId IdType="pubmed">26022924</ArticleId></ArticleIdList></Reference><Reference><Citation>Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Jonsson P, Birve A, Marklund SL, Graffmo KS, Forsberg K, Br&#xe4;nnstr&#xf6;m APM. Extensive size variability of the GGGGCC expansion in C9orf72 in both neuronal and non-neuronal tissues in 18 patients with ALS or FTD. Hum Mol Genet. 2015;24:3133&#x2013;3142. doi: 10.1093/hmg/ddv064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddv064</ArticleId><ArticleId IdType="pubmed">25712133</ArticleId></ArticleIdList></Reference><Reference><Citation>van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN, Brown PH, Baker MC, Finch NA, Bauer PO, Serrano G, Beach TG, Josephs KA, Knopman DS, Petersen RC, Boeve BF, Graff-Radford NR, Boylan KB, Petrucelli L, Dickson DW, Rademakers R. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 2013;12:978&#x2013;988. doi: 10.1016/S1474-4422(13)70210-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70210-2</ArticleId><ArticleId IdType="pmc">PMC3879782</ArticleId><ArticleId IdType="pubmed">24011653</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;bers A, Marroquin N, Schmoll B, Vielhaber S, Just M, Mayer B, H&#xf6;gel J, Dorst J, Mertens T, Just W, Aulitzky A, Wais LAC, Kubisch C, Weishaupt JH, Volk AE. Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. Neurobiol Aging. 2014;35:1214.e1&#x2013;e6. doi: 10.1016/j.neurobiolaging.2013.11.034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2013.11.034</ArticleId><ArticleId IdType="pubmed">24378086</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson JL, Finch NA, Baker MC, Kachergus JM, DeJesus-Hernandez M, Pereira K, Cristopher E, Prudencio M, Heckman MG, Thompson EA, Dickson DW, Shah J, Oskarsson B, Petrucelli L, Rademakers R, van Blitterswijk M. Elevated methylation levels, reduced expression levels, and frequent contractions in a clinical cohort of C9orf72 expansion carriers. Mol Neurodegener. 2020;15:7. doi: 10.1186/s13024-020-0359-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-0359-8</ArticleId><ArticleId IdType="pmc">PMC6993399</ArticleId><ArticleId IdType="pubmed">32000838</ArticleId></ArticleIdList></Reference><Reference><Citation>Maranzano A, Poletti B, Solca F, Torre S, Colombo E, Far&#xe9; M, Ferrucci R, Carelli L, Verde F, Morelli C, Silani V, Ticozzi N. Upper motor neuron dysfunction is associated with the presence of behavioural impairment in patients with amyotrophic lateral sclerosis. Eur J Neurol. 2022;29:1402&#x2013;1409. doi: 10.1111/ene.15243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15243</ArticleId><ArticleId IdType="pubmed">34989063</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, Carelli L, Lunetta C, Ticozzi N, Silani V. Advance care planning and mental capacity in ALS: a current challenge for an unsolved matter. Neurol Sci. 2020;41:2997&#x2013;2998. doi: 10.1007/s10072-020-04462-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04462-x</ArticleId><ArticleId IdType="pubmed">32435995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>